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The SR Protein SRp38
Represses Splicing in M Phase Cells
in Manley and Tacke, 1996; Graveley, 2000). SR proteins,
of which approximately a dozen have been described
in mammalian systems, are modular, containing one or
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two N-terminal RNP-type RNA binding domains (RBD)New York, New York 10027
and a C-terminal region consisting largely of multiple
Arg-Ser dipeptide repeats (RS domain). They play multi-
ple roles in splicing and have the unusual property ofSummary
functioning as both general, essential factors in consti-
tutive splicing and as regulators of alternative splicing. InSR proteins constitute a family of pre-mRNA splicing
constitutive splicing, the proteins play largely redundantfactors that play important roles in both constitutive
functions such that any single SR protein is able toand regulated splicing. Here, we describe one member
cooperate with the remainder of the splicing machineryof the family, which we call SRp38, with unexpected
to activate splicing in vitro. For this function, sequence-properties. Unlike other SR proteins, SRp38 cannot
specific interactions with the pre-mRNA likely play aactivate splicing and is essentially inactive in splicing
minimal role and instead, cooperative, RS domain-medi-assays. However, dephosphorylation converts SRp38
ated protein-protein interactions facilitate and stabilizeto a potent, general repressor that inhibits splicing at
snRNP interactions both with the pre-mRNA and withan early step. To investigate the cellular function of
each other (e.g., Wu and Maniatis, 1993; Kohtz et al.,SRp38, we examined its possible role in cell cycle
1994). In alternative splicing, SR proteins can activatecontrol. We show first that splicing, like other steps
splice site selection by distinct mechanisms. In one,in gene expression, is inhibited in extracts of mitotic
they function as in constitutive splicing, but if the mRNAcells. Strikingly, SRp38 was found to be dephosphory-
precursor contains competing 5 and/or 3 splice sites,lated specifically in mitotic cells, and we show that
utilization of specific pairs is determined by a combina-dephosphorylated SRp38 is required for the observed
tion of the splice site sequence and position in the pre-splicing repression.
mRNA and by the SR proteins’ identity and concentra-
tion (e.g., Ge and Manley, 1990; Krainer et al., 1990;Introduction
Zahler et al., 1993). Another mechanism involves se-
quences in mRNA called exonic splicing enhancersSplicing of mRNA precursors is not only a nearly ubiqui-
(ESEs; see Smith and Valcarcel, 2000; Blencowe, 2000,tous and essential step in gene expression, but it is
for reviews). ESEs function by binding combinations ofalso an important mechanism for generation of protein
SR proteins, which interact with general splicing factorsdiversity and regulation of gene expression. There are
to facilitate utilization of adjacent splice sites. Recogni-numerous examples where alternative splicing and its
tion of ESEs requires sequence-specific binding, and inregulation play key roles in cell growth control, differenti-
keeping with this, SR protein function in ESE recognitionation, and disease (reviewed by Graveley, 2001; Gra-
is largely nonredundant. Although initially thought to bebowski and Black, 2001). Indeed, it has been estimated
associated only with regulated splicing, more recentthat expression of 35% or more of human genes involves
studies have indicated that ESEs can function as partalternative splicing (e.g., Mironov et al., 1999). Given the
of constitutively spliced exons (Schaal and Maniatis,frequency, importance, and complexity of alternative
1999).splicing, it is not surprising that the process is subject
The RS domains of SR proteins are extensively modi-
to diverse and sophisticated forms of regulation (re-
fied by phosphorylation (reviewed by Misteli, 1999). At
viewed by Smith and Valcarcel, 2000). An interesting
least two kinases, SRPK1 (Gui et al., 1994) and Clk/Sty
principal that has emerged from studies to date is that (Colwill et al., 1996), have been shown to phosphorylate
regulation of splice site choice is frequently achieved by SR proteins. The phosphorylation status of SR proteins
combinatorial interactions between RNA binding proteins influences protein-protein interactions (Xiao and Man-
that interact with sequences in the mRNA precursor to ley, 1997, 1998) and, likely reflecting this, their sub-
influence interactions involving the general splicing ma- nuclear distribution (Misteli et al., 1997). Both hypo- and
chinery. Unlike with transcription, where regulation is hyperphosphorylation can reduce splicing activity (Ka-
frequently initiated by high-affinity, sequence-specific nopka et al., 1998; Prasad et al., 1999), suggesting that
DNA binding proteins, in many cases splicing regulation RS domain phosphorylation is tightly controlled.
is brought about by cooperative interactions between Analogous to the situation with transcription, repres-
factors that by themselves have more limited sequence sor proteins also play significant roles in splicing control.
specificity and affinity. As with transcription, however, And again as with transcription, several mechanisms
these factors can act either positively or negatively. Key seem to be utilized in splicing repression. The simplest
proteins in these regulatory complexes are frequently is competitive binding, and the well-studied Drosophila
members of the SR and hnRNP protein families. Sex-lethal protein (e.g., Valcarcel et al., 1993) and the
The SR proteins constitute a group of splicing factors mammalian polypyrimidine tract binding protein (e.g.,
that are highly conserved throughout metazoa (reviewed Chan and Black, 1997) provide examples of this mecha-
nism. The hnRNP A proteins antagonize the activity of
SR proteins in alternative splicing (Mayeda and Krainer,1Correspondence: jlm2@columbia.edu
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Figure 1. Isolation and Characterization of
SRp38
(A) Diagram of SRp38 derivatives. Features of
SRp38 and SRp38-2 are indicated. Numbers
represent amino acid residues.
(B) Coomassie blue staining of purified re-
combinant proteins used in this study. His-
tagged SRp38 (His-SRp38) was prepared
from baculovirus-infected Sf9 cells (lane 1).
Dephosphorylated His-tagged SRp38 (His-
dSRp38) was prepared by treatment with CIP
and repurified using Ni2 beads (lane 2).
(C) Expression pattern of SRp38 and SRp38-2
in selected tissues of adult mice. Equal
amounts of total protein were loaded in each
lane. HeLa cell lysate was also included. Pro-
teins were analyzed by Western blotting with
anti-SRp38 and anti-actin antibodies.
(D) SRp38, dSRp38 and SRp38-2 are present
in HeLa nuclear extract. HeLa cell lysate (lane
1), S100 extract (lane 2), nuclear extract (lane
3), and CIP-treated nuclear extract (lane 4)
were analyzed by Western blotting with anti-
SRp38 antibody. dSRp38 is indicated by the
arrow.
1992) and can also prevent splicing by binding to exonic Among those uncovered was a protein with strong se-
quence similarity to SR proteins. Two forms of this pro-elements known as exonic splicing silencers (ESSs; re-
tein, likely arising from alternative splicing, were recov-viewed in Smith and Valcarcel, 2000), although the
ered. Strengthening the similarity with SR proteins, themechanism(s) involved are not known. In Drosophila,
RBD showed the highest homology with that of the clas-the P element somatic repressor (PSI) represses splicing
sical SR protein SC35 (46% identity). Based on theby recruiting U1 snRNP to an upstream, psuedo 5 splice
apparent size of the proteins, and in keeping with thesite, preventing recognition of the authentic site (La-
naming system used for most SR proteins, we callbourier et al., 2001). Two proteins with similarity to SR
the full-length protein SRp38 and the smaller formproteins, RSF1 in Drosophila (Labourier et al., 1999) and
SRp38-2 (see Figure 1A). During the course of theseSRrp86 in mammals (Barnard and Patton, 2000), func-
studies, several other groups identified proteins thattion by interfering directly with other SR protein-medi-
appear to be identical to SRp38 and SRp38-2, calledated interactions. Finally, SR proteins themselves can
TASR-2 and -1 (Yang et al., 1998, 2000), NSSR-1 and -2under some conditions repress splicing, as with an ade-
(Komatsu et al., 1999), and SRrp40 (Cowper et al., 2001).novirus pre-mRNA, in which a binding site for the SR
Consistent with the protein’s sequence, these studiesprotein ASF2/SF2 is positioned such that it blocks U2
all suggested possible roles in splicing (see Discussion).snRNP association with the pre-mRNA (Kanopka et al.,
As a first step toward characterizing the function of1996).
SRp38, we prepared recombinant proteins and antibod-In this paper, we describe an SR protein, SRp38 (also
ies. Neither SRp38 nor SRp38-2 could be expressedknown as NSSR-1 [Komatsu et al., 1999], TASR-2 [Yang
efficiently in E. coli, but both were expressed to highet al., 2000], and SRrp40 [Cowper et al., 2001]), with
levels in baculovirus-infected insect cells and were puri-unusual properties. Most significantly, SRp38, despite
fied from these cells, either as his-tagged (Figure 1B) ora typical SR protein structure, is a splicing repressor
GST fusion (not shown) proteins. Because of problemsthat is strongly activated by dephosphorylation. Sug-
with solubility, we have not pursued studies with SRp38-2,gesting a possible physiological role for SRp38, we show
and instead concentrated on full-length SRp38. Purifiedthat the protein becomes dephosphorylated during M
His-SRp38 was first used to produce rabbit anti-SRp38phase of the cell cycle. We also show that splicing,
antibodies, which were affinity purified with the SRp38like other processes in gene expression, is inhibited in
RBD. The purified antibodies were used to determineextracts prepared from mitotic cells. Under these condi-
SRp38 expression patterns in various mouse tissuestions, repression was found to be mediated by SRp38,
and in HeLa cells.indicating that cell cycle-specific dephosphorylation of
SRp38 is expressed in different tissues in distinctSRp38 plays a role in gene silencing during mitosis.
ways (Figure 1C). In ovary, testis, and uterus, both
SRp38 and SRp38-2 are highly expressed, and at com-
Results parable levels. In brain and lung, on the other hand,
SRp38 is strongly expressed, but SRp38-2 is barely de-
Isolation of SRp38 tectable. Neither protein is produced at significant levels
Previous work from our lab has described properties of in heart, kidney, or liver. In all the expressing tissues, a
the human splicing regulators Tra2 and Tra2 (Tacke et faint species could be detected with gel mobility slightly
al., 1998). To extend these studies, we used a yeast two- greater than SRp38 (designated dSRp38), which we
speculated might correspond to un-, or hypo-, phos-hybrid screen to identify potential interacting proteins.
Mitotic Splicing Repression
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Figure 2. SRp38 Is a Splicing Repressor Activated by Dephosphorylation
(A) Inhibition of pre-mRNA splicing by SRp38. The indicated amounts of baculovirus-produced SRp38 (His-SRp38) were added to HeLa NE
(lanes 2–6) and S100 complemented with 250 ng of SC35 (lanes 8–11) together with a 32P-labeled -globin pre-mRNA. Products of splicing
were analyzed by denaturing PAGE and autoradiography. Splicing intermediates and products are indicated schematically.
(B) Potent inhibition of splicing by dSRp38. Increasing amounts of His-dSRp38 (2.5 ng to 10 ng) were incubated with NE (lanes 2–4) and with
S100 complemented with 125 ng of SC35 (lanes 6–9).
(C) Characterization of splicing inhibition by dSRp38. His-dSRp38 (4 or 10 ng) was added to splicing reactions as follows: untreated (lanes 2
and 3, respectively), CIP-treated and repurified (lanes 4 and 5), CIP-treated in the presence of -glycerophosphate () and repurified (lanes
6 and 7), and mock-treated in the presence of  and repurified (lanes 8 and 9).
(D) CIP treatment does not affect SC35-activated splicing. SC35 was added to splicing reactions in S100 extracts (lanes 1–3) or in NE (lanes
5–7) as follows: untreated (lanes 1 and 5), CIP-treated and repurified (lanes 2 and 6), and CIP-treated and repurified in the presence of 
(lanes 3 and 7).
phorylated SRp38. To test this, and also to elucidate in fact repressed splicing of a human -globin pre-
mRNA (or other substrates), either when added to NESRp38 expression levels in HeLa cells, we performed
or to S100 supplemented with SC35 or ASF/SF2 (FigureWestern blots with HeLa whole-cell lysate, cytoplasmic
2A; results with other substrates and ASF/SF2 notextracts (S100), and nuclear extract either untreated (NE)
shown). Although near-complete inhibition could be ob-or treated with calf intestinal phosphatase (NECIP)
served, relatively large amounts of recombinant protein(Figure 1D). The pattern of expression in HeLa cells was
(500 ng) were required, and the significance of thisessentially identical to the mouse ovary/testis/uterus
repression was therefore unclear (see also below). Simi-pattern. Like other SR proteins, SRp38 was not detected
lar levels of repression were typically detected whetherin S100. In NE, CIP treatment converted SRp38 to a form
His-tagged SRp38 or GST-SRp38 (not shown) was em-with mobility identical to dSRp38, strongly suggesting
ployed. However, some preparations of GST-SRp38 re-that this form in fact corresponds to dephosphorylated
quired significantly less protein to achieve comparableSRp38.
repression, and this enhanced activity seemed to corre-
late with the presence of small amounts of a species
SRp38 Is a Splicing Repressor Activated with SDS gel mobility that suggests that it might corre-
by Dephosphorylation spond to unphosphorylated GST-SRp38.
We next wished to determine whether SRp38 behaves In light of the above results, we tested directly whether
like a typical SR protein; e.g., whether it can activate the phosphorylation status of SRp38 affects the pro-
splicing in extracts lacking SR proteins. Using an S100 tein’s activity in splicing assays. Purified SRp38 was
complementation assay, purified SRp38 (His- or GST- treated with CIP and repurified (Figure 1B; see Experi-
tagged) was unable to activate splicing of several differ- mental Procedures), and increasing amounts were
ent pre-mRNAs (results not shown). However, during added to splicing reactions with NE or S100 plus SC35
(Figure 2B). Splicing inhibition was again observed, butthe course of these experiments, we noticed that SRp38
Cell
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strikingly, the amounts of dSRp38 required for full re-
pression were greatly reduced. In both NE and S100,
less than 10 ng resulted in complete inhibition, sug-
gesting that dephosphorylated SRp38 was at least 50-
fold more effective at splicing repression than was phos-
phorylated SRp38. Identical results (not shown) were
obtained with two additional substrates, HIV-tat- and IgM
H-chain-derived pre-mRNAs, suggesting that dSRp38
acts as a general splicing repressor.
Especially in light of the unexpected magnitude of
the CIP-induced activation of splicing repression, it was
essential to rule out the possibility that inhibition might
have been due to an artifact of the CIP treatment. We
therefore performed several control experiments to ad-
dress this. In one, purified SRp38 was first incubated
alone, with CIP, with CIP plus the phosphatase inhibitor
-glycerophosphate (), or with  alone, and all four
preparations of SRp38 were then repurified. Only the
sample treated with CIP alone was dephosphorylated,
as judged by SDS-PAGE (results not shown), and only
this sample gave rise to splicing repression at the con-
centrations tested (4 and 10 ng; Figure 2C, lanes 4 and
5). In another experiment, SC35 (his-tagged, produced
from recombinant baculovirus-infected cells) was incu-
bated alone, with CIP, or with CIP plus , and repurified Figure 3. Characteristics of dSRp38-Mediated Splicing Repression
in a manner identical to that used with SRp38. In this (A) dSRp38 inhibits an early step in spliceosome assembly. Spliceo-
case, a larger amount of each sample (100 ng) was some assembly assays were carried out in S100 extract comple-
added either to S100 or to NE, and effects on splicing mented with 125 ng of SC35 in the presence (lanes 5–8) or absence
(lanes 1–4) of 7.5 ng of His-dSRp38. Splicing complexes were re-were analyzed (Figure 2D). Not only did CIP-treated
solved by nondenaturing PAGE.SC35 show no inhibitory effect in NE (lanes 4–7), but it
(B) The target of splicing inhibition by dSRp38 is not an SR protein.also retained full activity in activating splicing in S100
Increasing amounts of SC35 (250 ng and 500 ng) were added to
(lanes 1–3). We conclude that the observed activation dSRp38-inhibited reactions as indicated (lanes 3 and 4).
of SRp38 as a splicing repressor by CIP was indeed due (C) The RS domain of SRp38 is required for potent repression. The
to dephosphorylation. indicated amounts of purified GST-SRp38 RBD (lanes 1–6), His-
SC35 RBD (lanes 7–11), and GST-hnRNP G RBD (lanes 12–16) were
added to splicing reactions containing-globin pre-mRNA substrateCharacteristics of dSRp38-Mediated
in S100 extract plus SC35.
Splicing Repression
To gain insight into the mechanism by which dSRp38
inhibits splicing, we first determined at which step splic- tude higher than the concentration of dSRp38 required
for inhibition (e.g., Figure 3B).ing was blocked. To this end, we performed spliceo-
some assembly assays, utilizing the -globin pre-mRNA Given that interactions with other SR proteins (which
are mediated by RS domains) are not the basis of dSRp38substrate and S100 extract activated with SC35, plus
or minus 7.5 ng dSRp38. The results of a time course repression, it was conceivable that splicing inhibition
was brought about by the RBD. To determine whether(Figure 3A) show that this amount of dSRp38 is sufficient
to prevent formation of complex A, which represents the SRp38 RBD was sufficient to repress splicing, we
purified from E. coli fusion proteins containing the re-the earliest step in spliceosome assembly detectable
by this method. We conclude that dSRp38 interferes lated RBDs from SRp38 and SC35, as well as from an
hnRNP protein, hnRNP G. The proteins were added towith interactions involving early acting factors, such as
U1 or U2 snRNP, branchsite recognition factors, and/ splicing reactions performed in S100 activated by SC35,
and the results (Figure 3C) show that both the SRp38or SR proteins.
We next examined whether dSRp38 activity involves and SC35 RBDs, but not the hnRNP G RBD, inhibited
splicing, although only at high concentrations. Notably,interactions with SR protein splicing activators. This was
tested first by asking whether increasing amounts of the amounts of either RBD and of full-length phosphory-
lated SRp38 (Figure 2A) required for splicing inhibitionSC35 could restore splicing inhibited by a small amount
of dSRp38. The results (Figure 3B) show that splicing were essentially identical. As full-length SC35 is a splic-
ing activator, repression brought about by the inactiveinhibition was not restored by increased levels of SC35,
indicating that SR proteins are not the targets of dSRp38 SC35 RBD likely reflects competitive interactions that
interfere with association of full-length SC35 with therepression activity. This is consistent with the fact that
dSRp38 was found to interact at most weakly with other pre-mRNA. It is likely that the similar weak repression
observed with both phosphorylated SRp38 and the iso-SR proteins in GST “pull-down”-type assays (although
phosphorylated SRp38 interacts strongly; see Discus- lated RBD reflect the same mechanism. Such “passive”
repression, which was also described recently by Cow-sion) (data not shown). Moreover, the amount of SR
protein required to activate splicing is an order of magni- per et al. (2001), may result only from the large excess
Mitotic Splicing Repression
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Figure 4. Pre-mRNA Splicing Is Inhibited in
Mitotic Cell Extracts
(A) Whole-cell extract preparation scheme
from asynchronous and nocodazol-arrested
(mitotic) HeLa cells. Untreated HeLa cells or
cells arrested in M phase were harvested,
suspended in low salt buffer, and homoge-
nized. Lysates were extracted with the indi-
cated NaCl concentrations, and extracts
were centrifuged and dialyzed. FACS results
of cells used in this preparation are shown
below the scheme.
(B) Inhibition of pre-mRNA splicing in mitotic,
but not asynchronous, high salt extracts.
Equal amounts of each whole-cell extract
prepared from asynchronous and mitotic
cells were tested for splicing activity with
-globin pre-mRNA.
of protein required, and thus may not be physiologically pre-mRNA (Figure 4B). With the asynchronous cells, all
three salt extractions gave rise to splicing competentrelevant. If this were the case, then phosphorylated
SRp38 would be inactive as a repressor, and phosphory- extracts, with the 2 M extract displaying the highest
activity. With the mitotic extracts, a strikingly differentlation/dephosphorylation would serve as an on/off
switch. pattern was observed. At 0.3 M, activity was essentially
the same as in the asynchronous extract. But activity
was significantly reduced in the 0.6 M extract and barely
Pre-mRNA Splicing Is Inhibited in Mitotic detectable in the 2 M extract. These results indicate
Cell Extracts both that the pre-mRNA splicing machinery is repressed
The results described above indicate that SRp38 has in extracts of mitotic cells, and that inhibition is mediated
the potential to be a strong, general repressor of splicing by (a) factor(s) that, in contrast with all the factors re-
that is activated by dephosphorylation. We next wished quired for splicing, require(s) high salt for solubilization.
to determine how these properties of SRp38 might con-
tribute to splicing control in vivo. One situation where
a phosphorylation-regulatable splicing repressor might SRp38 Is Dephosphorylated in M Phase
Having obtained evidence that the splicing machinerypotentially play a significant role is in M phase of the
cell cycle. It is well known that gene expression in mam- is repressed in mitotic extracts, we next wished to deter-
mine the phosphorylation status of SRp38 in mitoticmalian cells is generally inhibited during mitosis. Both
transcription (Segil et al., 1996; Akoulitchev and Rein- cells. We first treated HeLa cells with nocodazol for 24
hr (as in Figure 4) and prepared whole-cell lysates fromberg, 1998; Long et al., 1998) and polyadenylation (Col-
gan et al., 1996) of mRNA precursors are inhibited by the mitotic cells and from asynchronous cells. These
were analyzed by Western blotting with the anti-SRp38phosphorylation of key components, and cap-depen-
dent translation is also repressed, interestingly in this antibodies used above, with mAb104, which recognizes
a common phosphoepitope in the RS domain of SRcase by a mechanism involving dephosphorylation (Pyr-
onnet et al., 2001). However, whether or not the splicing proteins (Roth et al., 1991), and with a phosphorylation-
insensitive anti-ASF/SF2 polyclonal antibody (Figuremachinery is also inhibited in mitosis has not been inves-
tigated. 5A). Strikingly, the anti-SRp38 antibodies revealed accu-
mulation in the mitotic extract of a species with mobilityTo examine possible splicing inhibition during M
phase, we wished to prepare extracts from asynchro- consistent with it corresponding to dSRp38. Somewhat
unexpectedly (e.g., Gui et al., 1994), little change wasnously growing HeLa cells and from M phase cells (ar-
rested with nocodazol). However, a potential complicat- detected in the pattern of classical SR proteins, sug-
gesting that the phosphorylation status of these proteinsing factor is the fact that the nuclear envelope breaks
down during mitosis, and thus the standard nuclear ex- is not significantly altered as cells accumulate in M
phase. (SRp38 is recognized by mAb104, albeit moretract typically used to assay pre-mRNA splicing could
give misleading results. We therefore developed a whole- weakly than classical SR proteins. It was not resolved
from SRp40 in the gel shown.) To extend these results,cell extract procedure that should not be affected by
the status of the nuclear envelope (Figure 4A; see Experi- extracts prepared from HeLa cells at different times fol-
lowing release from a double-thymidine block were ana-mental Procedures). As part of the optimization of the
extract protocol, samples of the asynchronous and mi- lyzed by Western blotting, which revealed accumulation
of dSRp38 only in mitotic cells (Figure 5B).totic cell lysates were extracted with different NaCl con-
centrations, 0.3, 0.6, and 2 M, and the resultant extracts To confirm that the species detected in the M phase
lysates was in fact dSRp38, we analyzed by Westernwere used in splicing reactions, again with the -globin
Cell
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Figure 5. SRp38 Is Dephosphorylated in M Phase
(A) dSRp38 accumulates in M phase. Lysates of asynchronously grown HeLa cells (lanes 1 and 3) and mitotic cells arrested with nocodazol
(lanes 2 and 4) were analyzed by Western blotting with anti-SRp38, mAb104, anti-ASF/SF2 and anti-actin antibodies. A, asynchronous cell
lysates; M, mitotic cell lysates. Positions of SRp38 proteins and SR proteins are indicated.
(B) SRp38 expression through the cell cycle. Extracts from HeLa cells arrested at G1/S by double-thymidine block (lane 1), from cells released
from the block (lanes 2–8), and from cells arrested at M phase by 4 hr nocodazol treatment 8 hr after release (lane 9) were analyzed by Western
blotting with anti-SRp38 antibodies. FACS analysis indicated that mitotic cells accumulated from 10 to 14 hr after release (lanes 6–8).
(C) SRp38 is dephosphorylated in M phase cells. Whole-cell extracts from asynchronous (AE) and M phase (ME) cells were analyzed by
Western blotting with anti-SRp38 antibodies without (lanes 1 and 3) or with (lanes 2 and 4) treatment with CIP.
blotting asynchronous and M phase cell extracts treated tracts, partially blocked at 0.6 M, and nearly entirely
inhibited at 2 M. Remarkably, Western blotting revealedor not treated with CIP. The results (Figure 5C) show
that in the asynchronous cell extracts, CIP treatment that, while SRp38 and SRp38-2 were extracted equally
at all salt concentrations, dSRp38 was not present incompletely converted SRp38 to a more rapidly migrating
form with identical mobility to the species detected in the 0.3 M extract, but fully extracted in the 2.0 M extract
(compare with whole-cell lysate, Figure 5A) and presentM phase cells. Likewise, in M phase extracts, SRp38
was converted to the same rapidly migrating form, and at intermediate levels in the 0.6 M extract. To confirm
and extend these results, we focused on the fact thatno additional species were detected. (Blots with purified
recombinant SRp38 and dSRp38 indicated the antibod- 0.6 M NaCl gave an intermediate level of splicing inhibi-
tion and dSRp38 extraction. We therefore repeated theies used in this experiment recognized dSRp38 2-fold
more efficiently than SRp38 [results not shown], and above experiment, except using 0.7 M NaCl for the inter-
mediate salt concentration. Strikingly, splicing was sig-therefore, to facilitate comparisons of gel mobility, lower
amounts of the CIP-treated extracts were analyzed.) nificantly more inhibited at 0.7 M than at 0.6 M (Figure
6A; compare ME1 and ME2) and dSRp38 was also moreQuantitation of these and additional blots indicated that
the amount of dSRp38 increased from about 2% of the efficiently extracted (Figure 6B). Together, these results
provide a perfect correlation between splicing inhibitiontotal SRp38 protein in asynchronous cells to 30% in
mitotic cells. in mitotic cell extracts and the presence of dSRp38.
dSRp38 Is Necessary for MitoticPresence of dSRp38 Correlates
with Splicing Inhibition Splicing Repression
The correlation between the presence of dSRp38 andThe above results provided evidence that splicing is inhib-
ited in mitotic cell extracts by (a) factor(s) extracted at mitotic splicing repression, coupled with the fact that
SRp38 is abundant in HeLa cells (3  106 moleculeshigh salt, and that SRp38 becomes dephosphorylated
in M phase cells. If dSRp38 is responsible for M phase per cell; data not shown), strongly suggests that dSRp38
functions to repress the splicing machinery during mito-splicing repression, then it should be extracted from
mitotic extracts at high salt but not at low salt. To test sis. Consistent with this, addition of classical SR pro-
teins to mitotic extracts was unable to restore splicingthis, we first examined extracts prepared as in Figure
4, i.e., at 0.3, 0.6, and 2 M NaCl, both for splicing activity (results not shown), strengthening the conclusion that
they are not inactivated during mitotis. But to provide(Figure 6A) and for the presence of dSRp38 (Figure 6B).
As above, splicing was normal in the 0.3 M mitotic ex- more conclusive evidence for the role of dSRp38, we
Mitotic Splicing Repression
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Figure 6. Presence of dSRp38 Correlates with Splicing Inhibition
(A) Splicing activity of different whole-cell extracts. Equal amounts of whole-cell extracts prepared from asynchronous cells (AE) and two
preparations of mitotic cells (ME1 and ME2) extracted with the indicated salt concentrations were tested for splicing activity using -globin
pre-mRNA
(B) Extraction of dSRp38 from whole-cell extracts is salt sensitive. Extracts used in (A) were analyzed by Western blot with anti-SRp38 and
anti-actin antibodies.
wished to deplete repressed (i.e., high salt) mitotic ex- amount of dSRp38 necessary to effect complete inhibi-
tion (4 ng) was even less than observed with compara-tracts of dSRp38 and to determine whether such a de-
pleted extract becomes competent for splicing. Our ini- ble asynchronous extract (7.5 ng; see above). Addition
of phosphorylated SRp38 or other SR proteins (e.g.,tial attempts to do this using anti-SRp38 antibodies were
unsuccessful, as we were unable to deplete the protein ASF/SF2) was without effect (Figure 7D), confirming that
inhibition was specific to dSRp38.efficiently (results not shown). We therefore decided to
attempt to deplete the SRp38 proteins by another ap-
proach, RNA affinity. This method has been used before, Discussion
for example, to deplete the abundant hnRNP A1 proteins
from NE (Caputi et al., 1999), but requires knowledge of The experiments presented here provide evidence that
activation of a splicing repressor by dephosphorylationthe protein’s high-affinity RNA binding site. To deter-
mine this for SRp38, we performed SELEX (Tuerk and is important in inhibition of the splicing machinery during
M phase of the cell cycle. SRp38 thus behaves in aGold, 1990) with the GST-SRp38 RBD protein (see Ex-
perimental Procedures; Y. Feng, C.S., and J.L.M., un- distinctive manner, unlike previously characterized SR
proteins. Below we discuss the features of SRp38 thatpublished). The consensus sequence that emerged was
used to produce an 84 nucleotide biotinylated RNA con- might underlie these properties, the significance of mi-
totic splicing repression more generally, and finally thetaining three copies of the consensus motif (bio-C3),
and this was used to deplete SRp38 from mitotic extract role of dephosphorylation as an activating mechanism.
SRp38 has an overall primary structure typical of SRby binding to avidin beads. Figure 7A displays a Western
blot indicating that SRp38, dSRp38, and SRp38-2 were proteins, but its properties are quite atypical. Biochemi-
cally, SRp38 does not copurify with other SR proteinsall depleted from the bio-C3-treated extract, but not
from a mock-treated extract. Importantly, depletion was in the classical (NH4)2SO4-MgCl2 purification protocol
(Zahler et al., 1992; our unpublished results). Function-specific, as standard SR proteins were not significantly
removed (Figure 7A). ally, other known SR proteins are individually able to
activate splicing in extracts lacking SR proteins; SRp38We next compared the splicing activity of the mock-
and bio-C3-depleted extracts with untreated mitotic ex- has no detectable activating ability. The basis for these
differences is currently unknown, but likely reflects dif-tract (Figure 7B). Strikingly, the bio-C3-depleted extract
now displayed significant activity (lane 4), while the ferences in the RS domain. However, there is one prop-
erty that we believe SRp38 likely shares with other SRmock (lane 3) and untreated (lane 2) extracts remained
essentially inactive. To show that activation was due proteins, which is the ability to affect splicing both gen-
erally and in a sequence-specific manner. The general,specifically to removal of dSRp38, increasing amounts
of dSRp38 were added to the bio-C3-depleted extract or sequence-independent, activation function of SR pro-
teins, also referred to as exon-independent (Hertel and(Figure 7C). Splicing was again strongly repressed and,
in keeping with the fact that dSRp38 was not quantita- Maniatis, 1999), is driven by cooperative interactions
involving RS domain-mediated interactions with othertively removed from the mitotic extract (Figure 7A), the
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Figure 7. dSRp38 Is Necessary for Mitotic Splicing Repression
(A) Depletion of dSRp38 using RNA affinity. A biotinylated RNA containing three copies of the SRp38-selected consensus sequence (bio-C3)
and used to deplete endogenous dSRp38 from mitotic extract (lane 1). Bio-C3 RNA was immobilized with avidin agarose and incubated with
mitotic extracts (lane 3). Mock depletion was done with avidin agarose (lane 2). The resultant extracts were analyzed by Western blotting with
anti-SRp38 (lanes 1–3) and mAb104 (lanes 4–6) antibodies. (Detection of SRp20 is variable due to inconsistent transfer during blotting.) ME,
mitotic extract; mock, mock-depleted mitotic extract; bio-C3, mitotic extract depleted using biotinylated C3 RNA.
(B) Mitotic extract depleted of dSRp38 is competent for splicing. Extracts from (A) were tested for splicing activity using -globin pre-mRNA.
Mitotic extract, lane 2; mock-depleted mitotic extract, lane 3; dSRp38-depleted mitotic extract, lane 4. Standard nuclear extract (NE) was
used for comparison (lane 1).
(C) dSRp38 restores splicing repression to depleted mitotic extract. SRp38-depleted mitotic extract was supplemented with the indicated
amounts of His-dSRp38 (lanes 2 and 3) and analyzed for splicing activity.
(D) Restoration of splicing repression by dSRp38 is specific. The indicated proteins were added to SRp38-depleted extract and splicing
analyzed as above.
RS domain-containing general splicing factors. RBD- in brain (e.g., Komatsu et al., 1999), which has high
SRp38 levels but few mitotic cells.mediated interactions with the pre-mRNA, while neces-
sary (Zuo and Manley, 1993; Caceres and Krainer, 1993), SRp38 was identified previously by several different
approaches. TLS/FUS-associated SR proteins TASR-2are of less importance, and likely display relaxed se-
quence specificity. Given the general nature of repres- and -1, which correspond to SRp38 and SRp38-2, were
isolated from a yeast two-hybrid screen with TLS/FUSsion mediated by SRp38, it is likely that similar principles
underlie its mechanism of action. It has also been shown as bait (Yang et al., 1998, 2000). TLS/FUS is a member
of a family of proteins that associate with general tran-that the phosphorylation status of the splicing activator
ASF/SF2 strongly influences interactions with other pro- scription factors such as TFIID and RNA polymerase II
(RNAP II), as well as with SR protein splicing factors,teins (Xiao and Manley, 1997, 1998), and it is therefore
reasonable to believe that dephosphorylation of SRp38 and may thus function in linking transcription and RNA
processing (reviewed in Hirose and Manley, 2000). Neu-activates splicing repression by influencing protein-pro-
tein interactions. It is noteworthy that dephosphorylation ral salient SR proteins 1 and 2, corresponding to SRp38
and SRp38-2, were discovered with degenerate RBDof SRp38 weakens interactions with other SR proteins,
as this is opposite to the response observed with ASF/ and RS domain primers from a neural-enriched cDNA
library (Komatsu et al., 1999). In both the above studies,SF2 (Xiao and Manley, 1998). This could contribute to
repression, for example by disrupting required SR pro- transient cotransfection assays suggested that overex-
pression of the proteins influenced alternative splicingtein interactions.
It is likely that SRp38, like other SR proteins, pos- of reporter transcripts. SRrp40 (identical to SRp38) was
uncovered by database searching (Cowper et al., 2001).sesses sequence-specific activities in addition to its
general repression function. This is consistent with the As referred to above, recombinant SRrp40 displayed
repression activity at high concentrations, likely re-high-affinity, sequence-specific RNA binding we de-
tected by SELEX, and with the ability of phosphorylated flecting competition with activating SR proteins.
Our studies have shown that pre-mRNA splicing canSRp38 to interact with classical SR proteins and the
Tra2 splicing regulators (unpublished data). It is possible be strongly inhibited in mitotic cell extracts. Splicing
thus joins the other major steps in gene expression,that SRp38 cooperates with SR/Tra2 proteins to regulate
(positively and/or negatively) splicing of specific target transcription, polyadenylation, and translation, known
to be silenced in M phase. However, there is an intriguingtranscripts. Perhaps this reflects functions for example
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difference between the mechanisms by which splicing dephosphorylation, as well as to understand in more
and these other processes are repressed. In the other detail how dSRp38 mediates such efficient repression.
cases, specific essential general factors are inhibited: Our results have provided evidence that dephosphoryla-
subunits of TFIID (Segil et al., 1996) and TFIIH (Akoulit- tion of a splicing regulator can play an important role in
chev and Reinberg, 1998; Long et al., 1998) in RNAP II- cell cycle-dependent control of gene expression.
mediated transcription, poly(A) polymerase in 3 end
Experimental Proceduresformation (Colgan et al., 1996), and eIF4G in cap-depen-
dent translation (Pyronnet et al., 2001). In splicing, our
SRp38 cDNA Isolationdata suggest that the general splicing machinery is
Yeast two-hybrid screening was performed as described (Okamoto
largely if not entirely intact, as it can be extracted from et al., 1996). To isolate Tra2 interacting proteins, 107 trans-
mitotic cells in active form at low salt. The inhibition formants from cDNA libraries of human lymphocyte, HeLa, and
we observed was mediated instead by activation of a mouse fibroblast were screened. Database homology searching re-
vealed ten different clones, including two at the time unknown pro-specific repressor, SRp38. Given that the concentration
teins with structures typical of SR proteins, which we named SRp38of SRp38 is high and roughly equivalent to that of
and SRp38-2. PCR cloning was used to construct expression plas-snRNPs (106 /cell), dSRp38-induced repression is ca-
mids and these were confirmed by full-length sequencing.
pable of effectively silencing the splicing machinery dur-
ing M phase. Why the cell would use a dedicated repres- Antibody Production
sor to inhibit splicing is unclear. One possibility reflects Polyclonal antibodies were raised in rabbits (Cocalico Biologicals)
the fact that the massive, complex splicing machinery against full-length SRp38 or the RBD (used in Figure 5B). Both
antisera were affinity purified with the SRp38 RBD coupled to Affi-relies on numerous redundant components (e.g., SR
Prep 10 Support (Bio-Rad) beads using standard procedures (Har-proteins) to guarantee its precise functioning. It might
low and Lane, 1988). The anti-SRp38, but not the anti-RBD, antibod-therefore be difficult to silence splicing without inactivat-
ies recognized dSRp38 2-fold more efficiently than SRp38.ing many components; activation of a single repressor
could be more efficient. Another possibility is that leav- Mouse Tissues and HeLa Cells Western Blotting
ing the splicing machinery intact facilitates processing Mice (male and female) tissues were sectioned and immediately
of a possible class of mRNAs that must be produced frozen. Preparation of tissue samples was performed essentially as
described (Hanamura et al., 1998). HeLa cells grown on plates wereduring M phase; i.e., that are SRp38 resistant.
washed with cold PBS and lysed on the plates with protein SDSRegardless of the rationale for the existence of a
sample buffer. Whole-cell extracts prepared from HeLa cells re-mechanism employing an M phase-specific repressor,
leased from a double-thymidine block were the kind gift of Y. Xu.a more general question is why must the splicing ma-
chinery be actively repressed during mitosis? Might not
Recombinant Proteins
it be sufficient to block transcription to prevent synthesis His-SRp38, SC35 and ASF/SF2 and GST-SRp38 were prepared from
of new mRNAs, and polyadenylation to prevent matura- recombinant baculovirus-infected Sf9 cells. His-tagged recombi-
nant proteins were purified under denaturing conditions by Ni2tion of newly synthesized transcripts? One possibility is
agarose chromatography and renatured by dialysis (Tacke and Man-that splicing repression is a redundancy to ensure that
ley, 1995). GST-SRp38 RBD and hnRNP G RBD proteins were pre-inappropriate gene expression does not occur during
pared from E. coli JM101 using glutathione-Sepharose 4B. His-SC35mitosis. Another is that it is advantageous to the cell to
RBD was prepared from E. coli BL21 (Tacke and Manley, 1995).
shut down all processes that could compete or interfere Purity and concentration of proteins were determined by Coomassie
with the essential events of mitosis. Repression could blue staining of SDS gels.
also reflect a mechanism to prevent deleterious associa-
tion of nuclear spliceosomes with cytoplasmic compo- Dephosphorylation of Recombinant Proteins and Extracts
One hundred micrograms of His-tagged protein was incubated withnents, including mature mRNA, as a consequence of
100 units of CIP (NEB) for 30 min at 37C in phosphatase buffer (10nuclear envelope breakdown. Any or all of these scenar-
mM Tris-HCl [pH 8.0], 10 mM MgCl2, 70 mM NaCl, and 1 mM DTT),ios could explain the importance of mitotic splicing re-
where indicated in the presence of 50 mM -glycerophosphate, andpression.
repurified by Ni2 agarose chromatography as described above.
Activation of a mitotic regulator by dephosphorylation Quantitation of repurified proteins was carried out by silver staining
is relatively unusual; more typical are phosphorylation- and comparison with known standards and by Western blotting
mediated mechanisms involving direct phosphorylation using anti-histidine antibody (H-15, Santa Cruz Biotechnology) with
known amounts of His-tagged control proteins. Fifty micrograms ofby cdc2/cycin B. In addition to the factors mentioned
nuclear extracts, from asynchronous or mitotic cell extracts, wasabove that are important for synthesis of mRNA, factors
dephosphorylated by incubation with 30 units of CIP for 30 min atrequired for RNAP I and RNAP III transcription are inacti-
37C in phosphatase buffer and analyzed by Western blotting.vated by cdc2/cyclin B phosphorylation (reviewed by
Gottesfeld and Forbes, 1997), and phosphorylation of
In Vitro Splicing Assays
histones is important for proper chromosome conden- In vitro splicing was performed essentially as described (Tacke and
sation (e.g., Van Hooser et al., 1998). However, as men- Manley, 1995). Spliceosome assembly assays were performed as
tioned above, cap-dependent translation is inhibited described (Hirose et al., 1999).
during mitosis by dephosphorylation (Pyronnet et al.,
Whole-Cell Extract Preparation2001). It is unclear why translation and splicing utilize
For isolation of M phase HeLa cells, nocodazol (Sigma) was addeddephosphorylation as the final step in mitotic repres-
to a final concentration of 40 ng ml1 as described (Colgan et al.,sion. It is notable, however, that SRp38 contains only
1996). After 24 hr, 95% of the cells were arrested in M phase, as
two SP (or TP) dipeptides, required for cdk phosphoryla- determined by fluorescence-activated cell sorting. Whole-cell ex-
tion, and neither of these match the cdk consensus, tracts were prepared from asynchronous and mitotic cells as de-
S/TPXR/K. It will be important in the future to identify the scribed in Manley et al. (1980) with modifications. HeLa cells (109
cells) were collected, washed with cold PBS, and swollen in 18 mlM phase-specific phosphatase responsible for SRp38
Cell
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of Buffer A (Dignam et al., 1983) for 10 min on ice. Swollen cells transcription initiation by RNA polymerase II in a soluble extract
from isolated mammalian nuclei. Nucleic Acids Res. 11, 1475–1489.were lysed by homogenization with 10 strokes using a tight pestle
(Kontes). Six milliliter aliquots of each cell lysate were mixed with Ge, H., and Manley, J.L. (1990). A protein factor, ASF, controls cell-
3 ml Buffer C (Dignam et al., 1983), except containing NaCl to give specific alternative splicing of SV40 early pre-mRNA in vitro. Cell
final concentrations of 0.3, 0.6, 0.7, or 2 M for 30 min at 4C. The 62, 25–34.
resultant extracts were centrifuged at 40,000 rpm in a Beckman 50
Gottesfeld, J.M., and Forbes, D.J. (1997). Mitotic repression of theTi rotor for 1 hr at 4C, and supernatants were dialyzed against
transcriptional machinery. Trends Biochem. Sci. 22, 197–202.buffer D (Dignam et al., 1983). Extracts were quick-frozen and stored
Grabowski, P.J., and Black, D.L. (2001). Alternative RNA splicing inat 80C.
the nervous system. Prog. Neurobiol. 65, 289–308.
Graveley, B.R. (2000). Sorting out the complexity of SR protein func-Depletion of dSRp38 Using RNA Affinity
tions. RNA 6, 1197–1211.SELEX with purified GST-SRp38 RBD was performed for eight
rounds essentially as described (Tacke and Manley, 1995). Three Graveley, B.R. (2001). Alternative splicing: increasing diversity in the
copies of the DNA sequence corresponding to the consensus (5- proteomic world. Trends Genet. 17, 100–107.
ACAAAGACAAA) were subcloned into pGEM3 as described (Tacke
Gui, J.F., Lane, W.S., and Fu, X.D. (1994). A serine kinase regulates
and Manley, 1995), and biotinylated C3 RNA (bio-C3 RNA) was tran-
intracellular localization of splicing factors in the cell cycle. Nature
scribed in the presence of 0.4 mM biotin-16-UTP (Enzo Life Sci-
369, 678–682.
ences) and 1.5 mM UTP with SP6 RNA polymerase. Fifty micrograms
Hanamura, A., Caceres, J.F., Mayeda, A., Franza, B.R., Jr., andof bio-C3 RNA was bound to 100	l of avidin-agarose beads (Sigma).
Krainer, A.R. (1998). Regulated tissue-specific expression of antago-After washing with buffer D, the beads were divided into two ali-
nistic pre-mRNA splicing factors. RNA 4, 430–444.quots. Two tubes of beads were prepared for mock depletion; 300
	l of mitotic extract was added to the first batch of mock beads or Harlow, E., and Lane, D. (1988). Antibodies: A Laboratory Manual
bio-C3 RNA beads and rocked for 4 hr at 4C. After a brief spin, (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).
the supernatant was transferred to the next tube and the process Hertel, K.J., and Maniatis, T. (1999). Serine-arginine (SR)-rich splic-
repeated. Depletion experiments were repeated three times with ing factors have an exon-independent function in pre-mRNA splic-
variations in splicing activity of no more than 20%. ing. Proc. Natl. Acad. Sci. USA 96, 2651–2655.
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